`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`ADAPT PHARMA LIMITED, and
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owners.
`__________________
`
`Case No. IPR2019-00691
`U.S. Patent No. 9,561,177
`__________________
`
`JOINT AMENDED MANDATORY NOTICES OF
`PATENT OWNERS ADAPT PHARMA LIMITED AND
`OPIANT PHARMACEUTICALS, INC.
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owners Adapt Pharma Limited
`
`Case No. IPR2019-00691
`U.S. Patent No. 9,561,177
`
`
`
`(“Adapt”) and Opiant Pharmaceuticals, Inc. (“Opiant”) jointly submit the
`
`following amended mandatory notices:
`
`I.
`
`Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)
`Adapt and Opiant are the assignees, and Adapt Pharma Operations Limited,
`
`a wholly owned subsidiary of Adapt, is a limited exclusive licensee, of U.S. Patent
`
`No. 9,561,177 and U.S. Patent No. 9,775,838. Opiant is the assignee, and Adapt
`
`Pharma Operations Limited is a limited exclusive licensee, of U.S. Patent No.
`
`9,211,253; U.S. Patent No. 9,468,747; and U.S. Patent No. 9,629,965.
`
`Adapt is a wholly owned subsidiary of Emergent Acquisitions Limited.
`
`Emergent Acquisitions Limited is a wholly owned subsidiary of Emergent
`
`International Inc., which is a wholly owned subsidiary of Emergent BioSolutions
`
`Inc. Emergent BioSolutions Inc. is a publicly held company, and no publicly held
`
`company owns 10% or more of Emergent BioSolutions Inc.’s stock. Opiant is a
`
`publicly held company, and no publicly held company owns 10% or more of
`
`Opiant’s stock.
`
`II. Related Matters, 37 C.F.R. § 42.8(b)(2)
`Petitioner Nalox-1 Pharmaceuticals, LLC (“Nalox-1”) has filed the
`
`following related petitions for inter partes review:
`
`
`
`2
`
`
`
`Case No. IPR2019-00691
`
`US. Patent No. 9,561,177
`
`., usnm.um
`
`
`
`US. Patent No. 9,211,253; US. Patent No. 9,468,747; US. Patent No.
`
`9,561,177; US. Patent No. 9,629,965; and US. Patent No. 9,775,838 are being
`
`asserted in Adapt Pharma Operations Ltd., et a]. v. Teva Pharmaceuticals USA,
`
`Inc., et al., Case 2: l6-cv-07721-JLL-JAD (D.N.J.) (consolidated), filed October
`
`21, 2016; and Adapt Pharma Operations Ltd, et a]. v. Perrigo UK FINCO Limited
`
`Partnership, Case 2: 18-cv-15287-JLL-JAD (D.N.J.), filed October 25, 2018.
`
`Administrative matters that would be or could be affected by this proceeding
`
`include pending US. patent applications 15/415,221; 15/494,270; and 16/131,641.
`
`
`
`
`III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)
`Adapt designates the following attorney as lead counsel:
`
`Case No. IPR2019-00691
`U.S. Patent No. 9,561,177
`
`Jessamyn S. Berniker
`Reg. No. 72,328
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`jberniker@wc.com
`
`Opiant designates the following attorney as first backup counsel:
`
`Robert F. Green
`Reg. No. 27,555
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`rgreen@greengriffith.com
`
`Adapt designates the following attorneys as backup counsel:
`
`David M. Krinsky
`Reg. No. 72,339
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`dkrinsky@wc.com
`
`Anthony H. Sheh
`Reg. No. 70,576
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5436
`F: (202) 434-5029
`asheh@wc.com
`
`4
`
`
`
`
`
`Case No. IPR2019-00691
`U.S. Patent No. 9,561,177
`
`Opiant designates the following attorney as backup counsel:
`
`Jessica Tyrus Mackay
`Reg. No. 64,742
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`jmackay@greengriffith.com
`
`Powers of attorney appointing these attorneys to transact all business in this
`
`proceeding on behalf of Adapt or Opiant, respectively, have been submitted or will
`
`be submitted with this amended mandatory notice information.
`
`IV. Service Information, 37 C.F.R. § 42.8(b)(4)
`Counsel for Adapt and Opiant submit the following service information:
`
`Electronic mail addresses:
`
`Postal mail addresses:
`
`Telephone numbers:
`
`Facsimile number:
`
`
`
`jberniker@wc.com,
`dkrinsky@wc.com,
`asheh@wc.com, tkenner@wc.com,
`rgreen@greengriffith.com,
`jmackay@greengriffith.com
`Jessamyn S. Berniker
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`Jessica Tyrus Mackay
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`
`(202) 434-5000, (313) 883-8000
`
`(202) 434-5029
`
`5
`
`
`
`Counsel for Adapt consent to electronic service by email at
`
`Case No. IPR2019-00691
`U.S. Patent No. 9,561,177
`
`
`
`jberniker@wc.com, dkrinsky@wc.com, asheh@wc.com, and tkenner@wc.com.
`
`Counsel for Opiant consents to electronic service by email at
`
`rgreen@greengriffith.com and jmackay@greengriffith.com.
`
`
`Date: April 12, 2019
`
`
`
`
`
`Respectfully submitted,
`
`
`/Jessamyn S. Berniker/
`Jessamyn S. Berniker (Reg. No. 72,328)
`David M. Krinsky (Reg. No. 72,339)
`Anthony H. Sheh (Reg. No. 70,576)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`jberniker@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`
`Counsel for Patent Owner
`Adapt Pharma Limited
`
`/Jessica Tyrus Mackay/
`Robert F. Green (Reg. No. 27,555)
`Jessica Tyrus Mackay (Reg. No. 64,742)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`jmackay@greengriffith.com
`
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`
`
`6
`
`
`
`Case No. IPR2019-00691
`
`US. Patent No. 9,561,177
`
`W
`
`Pursuant to 37 CPR. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on April 12, 2019, by delivering a
`
`copy via electronic mail on the following attorneys of record:
`
`Yelee Y. Kim
`
`Janine A. Carlan
`
`Richard Bennan
`
`Bradford Frese
`
`Christopher Yaen
`ARENT FOX LLP
`
`1717 K Street NW
`
`Washington, DC 20036
`Yelee.Kim@arentfox.com
`Janine.Carlan@arentfox.com
`Richard.Berman@arentfox.com
`Bradford.Frese@arentfox.com
`Christopher.Yaen@arentfox.com
`
`/Jessica Tyrus Mackay/
`Jessica Tyrus Mackay
`Reg. No. 64,742
`
`